<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20241021063443N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-12-23</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of lidocaine on quality of postoperative sleep</public_title>
      <acronym></acronym>
      <scientific_title>The effect of intraoperative lidocaine infusion compared to placebo on postoperative sleep quality in patients undergoing surgery for right lung hydatid cyst</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/79707</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Based on the sequence generated by the www.randomizatiom.ir, patients will be randomly assigned to one of two lidocaine or normal saline groups with a ratio of 1:1. Sequential numbers from 1 to 70 will be marked on envelope for each person. 35 sheets of paper marked L (lidocaine group) and 35 sheets marked N (normal saline group) will be sealed inside the envelopes. During the study, the technician opens the envelope and prepares the drugs according to the group specified in the L or N sheet. Normal saline will be exactly the same as lidocaine in terms of color, smell, volume and administration method, Blinding description: The patients, the anesthetist who administers the drug, and the assistant who collects the data, as well as the person who will analyze the data, will be blinded to the study groups.
The protocol and objectives of the study are explained to the patient, and after consent to participate in the study, the nurse prepares the medications according to the order of the prepared packets. Therefore, only the nurse knows whether the patient received lidocaine or placebo. Normal saline is considered a placebo, which is similar in appearance and smell to lidocaine. Therefore, the patient (due to lack of consciousness), the anesthesiologist and assistant who collects information after the operation, as well as the person who analyzes, have no information about the receipt of lidocaine or placebo.</study_design>
      <phase>3</phase>
      <hc_freetext>Right lung hydatid cyst.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Continuous infusion of 2 mg/kg/hour of 2% lidocaine ampoule (100 mg in 5cc) produced by Caspian Company during surgery using an JMS Syringe pump SP-500. Intervention 2: Control group: Continuous infusion of 2 mg per kg per hour normal saline during the surgery using an infusion pump -model SP500-JMS.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shabnam Niroumand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 22, South Bozorgmehr 13, Sajjad Blvd</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>918661865</zip>
        <telephone>+98 51 3841 2081</telephone>
        <email>niroumandsh@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shabnam Niroumand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 22, South Bozorgmehr 13, Sajjad Blvd</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>918661365</zip>
        <telephone>+98 51 3841 2081</telephone>
        <email>niroumandsh@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who are candidates for lung hydatid cyst surgery
Patients aged 18-50 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>leep disorder before entering the study (in the patient's self-report or the anesthesiologist's examination)
Taking sleeping pills before entering the study
Having a history of addiction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B67</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Echinococcosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Continuous infusion of 2 mg/kg/hour of 2% lidocaine ampoule (100 mg in 5cc) produced by Caspian Company during surgery using an JMS Syringe pump SP-500</i_keyword>
      <i_keyword>Control group: Continuous infusion of 2 mg per kg per hour normal saline during the surgery using an infusion pump -model SP500-JMS</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sleep quality after surgery based on Pittsburgh Sleep Quality Index (PSQI) score. Timepoint: Determining Sleep quality before surgery and day 1 and 3 after surgery. Method of measurement: Using the Pittsburgh Sleep Quality Index (PSQI) questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The dose of remifentanil used during the operation. Timepoint: Immediately after surgery. Method of measurement: Measuring the dose of remifentanil used during anesthesia,.</sec_outcome>
      <sec_outcome>The presence of cough within 5 minutes after the ex-tube and also the cough scores. Timepoint: Immediately after surgery. Method of measurement: Based on the 4-point Minogue scale.</sec_outcome>
      <sec_outcome>The score of pain after the operation. Timepoint: Immediately after surgery. Method of measurement: Based on Visual Analog Scale.</sec_outcome>
      <sec_outcome>The occurrence of nausea and vomiting after the operation. Timepoint: Immediately after surgery. Method of measurement: Based on self expression and observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-08-05</approval_date>
        <contact_name>Ethics committee of Imam Reza Hospital, Mashhad University of Medical Sciences</contact_name>
        <contact_address>Faculty of Medicine, Mashhad University of Medical Sciences, Azadi Square, Mashhad, Khorasan Razavi Province, Iran Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
